However, recent drug-target association studies have revealed that among multiple triglyceride-lowering therapeutic targets—including PPARA, ANGPTL3, ANGPTL4, APOC3, and LPL—only lipoprotein lipase (LPL) activation reduces the risk of NAFLD. This evidence concerns the gene LPL and metabolic dysfunction-associated steatotic liver disease.